 |
|
recombinant human EGF-rP64K/Montanide ISA 51 vaccine
A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Previous: | recombinant fowlpox-prostate apecific antigen vaccine, recombinant fowlpox-TRICOM vaccine, recombinant fowlpox-tyrosinase vaccine, recombinant human 6Ckine, recombinant human chorionic gonadotropin | | Next: | recombinant human endostatin, recombinant human growth hormone, recombinant human hyaluronidase, recombinant human interleukin-21, recombinant human stem cell factor |
|
|
